| Abstrakt: |
Intravenous immunoglobulins (IVIGs) have been used as a replacement therapy for primary immunodeficiency for many years. I n other neurological systemic autoimmune conditions I VIGs have proven beneficial, often when the patient has been unresponsive to other therapies and interventions. While some conditions, such as Guillain Barré syndrome, can be managed with a single course, many other long-term/progressive diseases require repeated infusions. I VIGs are expensive and the cost is increasing, largely due to global shortages and increased demand. Measures to prioritize the use of the product are based on clinical need, where there is evidence of effectiveness and where the benefits outweigh potential risks. This paper aims to explain the mechanism of action of immunoglobulin therapy and review some of the benefits and risks associated with their administration. [ABSTRACT FROM AUTHOR] |
